Experimental Drug Bests Chemo in Non-Small Cell Lung Ca... ( TUESDAY July 5 (Healt...)

Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study

Date:7/5/2011

TUESDAY, July 5 (HealthDay News) -- A drug designed to treat certain patients with non-small cell lung cancer boosts survival time without progression of cancer by several months, according to a new study.

The findings reveal that the drug, known as erlotinib (brand name Tarceva), doesn't just boost lifespan, said Dr. Neal E. Ready, associate professor of medical oncology at Duke Cancer Institute, who was not involved with the study. "What you really get is a prolonged period of time when the cancer is under control and someone has a really good quality of life."

This study is the first of its kind to look at Western patients. "Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to [non-small cell lung cancer] therapy compared to Western populations," said principal investigator Dr. Radj Gervais, of the Centre Francois Baclesse in Caen, France, in a news release from the International Association for the Study of Lung Cancer. The association is hosting the World Conference on Lung Cancer in Amsterdam, where the study results were scheduled for presentation Tuesday.

The study of the drug is a phase 3 study. That means it's in the final of three stages of testing that drugs undergo before they can be approved for treatment of a specific disease.

The researchers randomly assigned 174 patients to either erlotinib or platinum-based chemotherapy. Preliminary results showed that about 55 percent of patients responded to the drug, compared to nearly 11 percent to chemotherapy. Patients lived without progression of cancer for 9.4 months with the drug compared to 5.2 months for those who received chemotherapy.

And the median survival was 22.9 months for those who took the drug compared to 18.8 months for those on chemotherapy, the investigators found. '/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
4. Experimental treatment offers relief from painful prostate condition
5. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
6. Experimental Test May Warn of Premature Births
7. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
8. Experimental Weight-Loss Drug Seems to Work: Study
9. Experimental drug achieves unprecedented weight loss
10. Science at a glance: Symposia, research and special events at Experimental Biology 2011
11. A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease

Post Your Comments:

Related Image:

Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study

(Date:6/17/2013)... New York (PRWEB) June 18, 2013 ... has more physicians listed in New York magazine's ... In the latest survey, 209 NewYork-Presbyterian physicians from ... fortunate to have some of the nation's best ... J. Corwin, CEO of NewYork-Presbyterian Hospital. "We are ...

(Date:6/17/2013)... and Drug Administration (FDA) imposes new graphic warning ... First Amendment challenge if they depict health consequences ... evidence, says a Georgetown University Medical Center public ... warning labelswhich combine images with health warningsare a ... other countries, but the tobacco industry argues they ...

(Date:6/17/2013)... MA (PRWEB) June 17, 2013 Daimer ... robust steam cleaner equipment , such as expertly designed ... launched the KleenJet® Pro Plus 200S for apartment dwellers ... up to 310°F in 15 minutes and pressure levels ... effectively. The machine can be used to clean carpet ...

(Date:6/17/2013)... Bust’DD (pronounced ‘busted’), a new company that ... women with large busts, will soon launch their crowdfunding campaign ... understand the problem of ill-fitting bras and want to offer ... is to raise at least $25,000 to create their beta ... on a wide scale. , In order to kick off ...

(Date:6/17/2013)... (PRWEB) June 17, 2013 Today, ... stand-alone HRAs for small businesses . Zane Benefits, ... employer sponsored health benefits, is the leader in ... arrangements . , According to Zane Benefits’ website, ... Accounts or HRAs, offer small businesses an affordable ...

Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List 2 Health News:Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge? 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 2 Health News:Daimer Ships Vapor Steam Cleaner For Homeowners 3 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2 Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3 Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2

[0] NewYork-Presbyterian Leads NY Metro Area Hospitals on New York Magazine's Annual ‘Best Doctors' List [0] Can new FDA graphic warning labels for tobacco pass a first amendment legal challenge?[0] Daimer Ships Vapor Steam Cleaner For Homeowners [0] Arizona Startup Bust’DD Looking to Start a BRAvolution [0] Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses

... , , , ... , the global leader in thin computing and client virtualization, today announced ... Smiles is a rapidly-growing company whose mission is to bring quality dental ... first office in 2002 in Atlanta, GA, the network has demonstrated substantial ...

... , , , ... Health, Inc. (Nasdaq: GHDX ) today announced that Kim ... Adams 29th Annual Global Growth Conference in Boston, on Thursday, August ... access the live and subsequently archived webcast of the presentation, visit ...

... , , , ... Aug. 6 CSC (NYSE: CSC ... company as a preferred provider to help member hospitals comply with the ... U.S. federal government stimulus package. Under the ARRA, hospitals will receive incentive ...

... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... of three MedCounselor consumer drug information modules for pharmacies and ... to take medications safely, assists in identifying unknown tablets or ... indispensable in helping to increase consumer compliance to their drug ...

... , KIBBUTZ SHAMIR, Israel, Aug. 6 Shamir ... to issue its second quarter of 2009 earnings results on Thursday, August ... at 11:00 A.M. EDT that morning. , , ... listen live, please go to www.kcsa.com approximately five ...

... Va., Aug. 6 Sunrise Senior Living, Inc. (NYSE: ... second quarter of 2009. Sunrise will host a conference call ... discuss the financial results. , , "Our restructuring ... expense controls. In recent weeks we have seen a modest lift ...

Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference CSC to Help Georgia Hospital Association Members Achieve 'Meaningful Use' of Electronic Health Records Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results Sunrise Reports Financial Results for Second-Quarter 2009

(Date:6/17/2013)... Perrigo Company (NYSE: PRGO ; ... agreement to acquire and has completed the acquisition of ... Fera Pharmaceuticals, LLC and its affiliates (Fera), a privately-held, ... pharmaceutical company. The acquired portfolio, including nine prescription ANDA ... during calendar year 2012. Terms of the transaction include ...

(Date:6/17/2013)... , June 17, 2013 AbbVie (NYSE: ... from a Phase I study of ABT-199/GDC-0199, an ... patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), ... High-risk CLL patients are those with deletions of ... fludarabine therapy. These data were presented at the ...

(Date:6/17/2013)... -- Life Technologies Corporation (NASDAQ: LIFE ... iPSC Reprogramming Vectors , the world,s first product to ... developers a Nobel Prize in 2012 for the ability ... embryonic state. Scientists use induced pluripotent stem ... somatic cells. The iPSCs can then be differentiated into ...

Breaking Medicine Technology:Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 2 Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 3 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 2 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 3 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 4 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 5 AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting 6 Life Technologies Expands Range of Stem Cell Reprogramming Solutions 2 Life Technologies Expands Range of Stem Cell Reprogramming Solutions 3

[0] Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million [0] AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting [0] Life Technologies Expands Range of Stem Cell Reprogramming Solutions

... " Two Years and Counting " White Paper ... Milestones and Educational Needs Elsevier ... more than 1,300 healthcare organizations, today announced the addition of a ... its eBook, A Guide to Education and Training for ICD-10 ...

... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... discovering breakthrough treatments for human disease, announced positive, ... 2 study in carcinoid syndrome with LX1032 ... condition caused by neuroendocrine tumors that usually originate ...

Cached Medicine Technology:Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 2 Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 3 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5

Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...

Bacterial/Viral Filters for Anesthesia and Respiratory Applications...

Medicine Products:

Medisize Ulti-Mist Filter 30303 Filter 5096 Filter 303HEPA Filter